Companies working in the health and life sciences industry – including pharmaceuticals, biotechnology, diagnostics and nutraceuticals – are experiencing a large-scale disruption. The future of healthcare is defined by radically interoperable data, open yet secure platforms and consumer-driven care. New technologies are emerging to deliver precision medication, gene therapy, consumer wearables, eHealth and telemedicine etc.
No matter how promising these technologies may be, the industry is faced with an enormous challenge: keeping healthcare affordable. At the same time, the industry is coping with an ageing population, an unstoppable wave of digitalisation, and a global COVID-19 pandemic. Companies and organisations that will manage to find innovative ways of delivering value in this environment will have the advantage.
